[Chemoprevention of cancer of the uterine cervix--preliminary study on the intervention of the cervical precancerous lesion by retinamide RII].
Twenty seven women with mild, moderate or severe cervical dysplasia proven by pathology were treated by retinamide RII suppository. Retinamide RII suppository, 10 mg QD, was given intravaginally for six months (three months as a course). Clinical examination, Papanicolaou cytology and tissue biopsy under colposcope were carried out before and after treatment. The results indicated that after the second course, 26 out of 27 patients responded; of them, precancerous lesions disappeared in 24 and even normal squamous epithelium was observed in 3. The overall response rate was 96.29% and the marked response rate was 88.89%. The general side effects were mild. There was little cervical and vaginal irritation which was well tolerated. The results of this clinical trial make available a practical base for chemoprevention of cervical cancer.
Chen
R D
RD
Cancer Institute, Chinese Academy of Medical Sciences, Beijing.
Wang
R Z
RZ
Luo
H Z
HZ
Liu
Y
Y
Bao
P Y
PY
Li
X L
XL
Li
F R
FR
Guo
Z R
ZR
Han
R
R
Li
L M
LM
D000970:Antineoplastic Agents; D002584:Cervix Uteri / Q000473:pathology; D005260:Female; D006801:Humans; D006965:Hyperplasia; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000473:pathology; D013488:Suppositories; D014212:Tretinoin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000517:prevention & control*
D000970:Antineoplastic Agents; D013488:Suppositories; D014212:Tretinoin; C054441:retinamide